RU2017120358A - Анти-il-1-бета антитела и способы их применения - Google Patents
Анти-il-1-бета антитела и способы их применения Download PDFInfo
- Publication number
- RU2017120358A RU2017120358A RU2017120358A RU2017120358A RU2017120358A RU 2017120358 A RU2017120358 A RU 2017120358A RU 2017120358 A RU2017120358 A RU 2017120358A RU 2017120358 A RU2017120358 A RU 2017120358A RU 2017120358 A RU2017120358 A RU 2017120358A
- Authority
- RU
- Russia
- Prior art keywords
- amino acid
- seq
- humanized antibody
- paragraphs
- sequence
- Prior art date
Links
- 150000001413 amino acids Chemical group 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 5
- 229940024606 amino acid Drugs 0.000 claims 4
- 235000001014 amino acid Nutrition 0.000 claims 4
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- -1 isoleucine amino acid Chemical class 0.000 claims 3
- 108050006617 Interleukin-1 receptor Proteins 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 108090000193 Interleukin-1 beta Proteins 0.000 claims 1
- 102000003777 Interleukin-1 beta Human genes 0.000 claims 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14192523 | 2014-11-10 | ||
| EP14192523.0 | 2014-11-10 | ||
| PCT/EP2015/075875 WO2016075034A1 (en) | 2014-11-10 | 2015-11-06 | ANTI-IL-1beta ANTIBODIES AND METHODS OF USE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017120358A true RU2017120358A (ru) | 2018-12-13 |
| RU2017120358A3 RU2017120358A3 (cg-RX-API-DMAC7.html) | 2019-05-29 |
Family
ID=51868114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017120358A RU2017120358A (ru) | 2014-11-10 | 2015-11-06 | Анти-il-1-бета антитела и способы их применения |
Country Status (15)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2537100T3 (es) | 2009-04-07 | 2015-06-02 | Roche Glycart Ag | Anticuerpos biespecíficos trivalentes |
| JP6946184B2 (ja) | 2014-11-10 | 2021-10-06 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗ｐｄｇｆ−ｂ抗体及び使用法 |
| WO2016075034A1 (en) | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | ANTI-IL-1beta ANTIBODIES AND METHODS OF USE |
| SG11201703458UA (en) | 2014-11-10 | 2017-05-30 | Hoffmann La Roche | Anti-ang2 antibodies and methods of use |
| KR20170080584A (ko) | 2014-11-10 | 2017-07-10 | 에프. 호프만-라 로슈 아게 | 이중특이적 항체 및 안과학에서 이의 사용 방법 |
| EP3227332B1 (en) | 2014-12-03 | 2019-11-06 | F.Hoffmann-La Roche Ag | Multispecific antibodies |
| WO2018212556A1 (en) * | 2017-05-16 | 2018-11-22 | Cj Healthcare Corporation | A method for purifying an antibody or an antibody fragment thereof using affinity chromatography |
| TWI679052B (zh) * | 2017-05-16 | 2019-12-11 | 南韓商Ｃｊ醫藥健康股份有限公司 | 使用親和力層析術純化抗體或其抗體片段的方法 |
| EP3638697A4 (en) | 2017-06-12 | 2021-07-07 | Bluefin Biomedicine, Inc. | ANTI-IL1RAP ANTIBODIES AND ANTIBODY INGREDIENT CONJUGATES |
| IL318916A (en) * | 2018-01-26 | 2025-04-01 | Genzyme Corp | FC variants with improved binding to FCRN and extended half-life |
| CN110818793A (zh) | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
| MY199149A (en) | 2018-12-21 | 2023-10-18 | Hoffmann La Roche | Antibody that binds to vegf and il-1beta and methods of use |
| CN115028723B (zh) * | 2019-03-07 | 2023-08-29 | 瑞阳(苏州)生物科技有限公司 | 人IL-1β蛋白结合分子及其编码基因和应用 |
| CN114026127B (zh) * | 2019-06-11 | 2024-10-29 | 生物蛋白有限公司 | 条件活性抗epcam抗体、抗体片段、其免疫缀合物以及其用途 |
| CN114524875B (zh) * | 2021-11-11 | 2023-07-25 | 江苏莱森生物科技研究院有限公司 | 偶联IL-1β单克隆抗体的纳米硅球及应用 |
| CN117126278B (zh) * | 2023-10-26 | 2024-01-05 | 中国科学院苏州纳米技术与纳米仿生研究所 | 一种单克隆抗体及其应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4935343A (en) * | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
| AU2003208946A1 (en) * | 2002-02-28 | 2003-09-16 | Eli Lilly And Company | Anti-interleukin-1 beta analogs |
| DK1517921T3 (da) | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
| CA2509136C (en) * | 2003-01-24 | 2013-10-29 | Applied Molecular Evolution, Inc. | Human il-1 beta antagonists |
| US20050226863A1 (en) * | 2003-11-20 | 2005-10-13 | Massachusetts Institute Of Technology | Single-domain antibodies and uses thereof |
| WO2005087812A1 (en) | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for vegf/pdgf family of growth factors |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| EP2391652A4 (en) * | 2009-01-29 | 2013-01-02 | Abbott Lab | IL-1 BINDING PROTEINS |
| EP2488201A4 (en) * | 2009-10-15 | 2013-12-25 | Abbvie Inc | IL-1 BINDING PROTEINS |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| MX2013001267A (es) * | 2010-08-13 | 2013-04-10 | Genentech Inc | ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD. |
| RU2013115927A (ru) * | 2010-09-10 | 2014-10-20 | Апексиджен, Инк. | АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ |
| CA2821976A1 (en) * | 2010-12-21 | 2012-09-13 | Abbvie Inc. | Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use |
| JP6069312B2 (ja) | 2011-06-29 | 2017-02-01 | アムジェン インコーポレイテッド | 腎細胞癌の治療における生存の予測バイオマーカー |
| EP2867360B1 (en) | 2012-06-28 | 2019-05-08 | Molecular Partners AG | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| US9695233B2 (en) | 2012-07-13 | 2017-07-04 | Roche Glycart Ag | Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases |
| KR20150060686A (ko) | 2012-09-28 | 2015-06-03 | 베링거 인겔하임 인터내셔날 게엠베하 | 이중 안지오포이에틴-2/Dll4 결합제 및 항-VEGF 제제를 포함하는 약제학적 조합물 |
| CN104661678A (zh) | 2012-09-28 | 2015-05-27 | 勃林格殷格翰国际有限公司 | 包含双重血管生成素-2/Dll4结合物和抗VEGF-R药剂的药物组合 |
| BR112015010566A2 (pt) | 2012-11-08 | 2017-07-11 | Clearside Biomedical Inc | métodos e dispositivos para o tratamento de doenças oculares em indivíduos humanos |
| EP2917237A1 (en) | 2012-11-09 | 2015-09-16 | Pfizer Inc. | Platelet-derived growth factor b specific antibodies and compositions and uses thereof |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| MX2015013166A (es) * | 2013-03-15 | 2015-12-11 | Abbvie Inc | Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17. |
| UA118029C2 (uk) * | 2013-04-29 | 2018-11-12 | Ф. Хоффманн-Ля Рош Аг | Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування |
| PE20160753A1 (es) | 2013-12-20 | 2016-08-01 | Hoffmann La Roche | Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40 |
| RU2727639C2 (ru) | 2014-01-15 | 2020-07-22 | Ф.Хоффманн-Ля Рош Аг | Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а |
| JP6946184B2 (ja) | 2014-11-10 | 2021-10-06 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗ｐｄｇｆ−ｂ抗体及び使用法 |
| SG11201703458UA (en) | 2014-11-10 | 2017-05-30 | Hoffmann La Roche | Anti-ang2 antibodies and methods of use |
| KR20170080584A (ko) | 2014-11-10 | 2017-07-10 | 에프. 호프만-라 로슈 아게 | 이중특이적 항체 및 안과학에서 이의 사용 방법 |
| WO2016075034A1 (en) | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | ANTI-IL-1beta ANTIBODIES AND METHODS OF USE |
| US20190004048A1 (en) | 2015-06-26 | 2019-01-03 | Amgen Inc. | Biomarker of Survival in the Treatment of Renal Cell Carcinoma with a VEGFR Inhibitor and an Ang2 Inhibitor |
| US11198726B2 (en) | 2017-06-02 | 2021-12-14 | Boerhinger Ingelheim International Gmbh | Anti-cancer combination therapy |
-
2015
- 2015-11-06 WO PCT/EP2015/075875 patent/WO2016075034A1/en not_active Ceased
- 2015-11-06 CA CA2963719A patent/CA2963719A1/en not_active Abandoned
- 2015-11-06 JP JP2017525023A patent/JP6787888B2/ja not_active Expired - Fee Related
- 2015-11-06 CN CN201580060880.4A patent/CN107074942A/zh active Pending
- 2015-11-06 EP EP15790945.8A patent/EP3218402A1/en not_active Withdrawn
- 2015-11-06 KR KR1020177015590A patent/KR20170081253A/ko not_active Withdrawn
- 2015-11-06 AU AU2015345320A patent/AU2015345320A1/en not_active Abandoned
- 2015-11-06 BR BR112017009817A patent/BR112017009817A2/pt not_active Application Discontinuation
- 2015-11-06 SG SG11201702550WA patent/SG11201702550WA/en unknown
- 2015-11-06 RU RU2017120358A patent/RU2017120358A/ru not_active Application Discontinuation
- 2015-11-06 MX MX2017005987A patent/MX2017005987A/es unknown
- 2015-11-09 AR ARP150103647A patent/AR102594A1/es unknown
- 2015-11-09 TW TW104136907A patent/TW201632552A/zh unknown
-
2017
- 2017-03-14 IL IL251165A patent/IL251165A0/en unknown
- 2017-05-09 US US15/590,161 patent/US10344085B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| IL251165A0 (en) | 2017-04-30 |
| BR112017009817A2 (pt) | 2018-02-14 |
| KR20170081253A (ko) | 2017-07-11 |
| CA2963719A1 (en) | 2016-05-19 |
| US10344085B2 (en) | 2019-07-09 |
| TW201632552A (zh) | 2016-09-16 |
| CN107074942A (zh) | 2017-08-18 |
| RU2017120358A3 (cg-RX-API-DMAC7.html) | 2019-05-29 |
| AR102594A1 (es) | 2017-03-08 |
| EP3218402A1 (en) | 2017-09-20 |
| JP6787888B2 (ja) | 2020-11-18 |
| US20170247447A1 (en) | 2017-08-31 |
| JP2017534646A (ja) | 2017-11-24 |
| AU2015345320A1 (en) | 2017-04-06 |
| MX2017005987A (es) | 2017-06-29 |
| SG11201702550WA (en) | 2017-04-27 |
| WO2016075034A1 (en) | 2016-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017120358A (ru) | Анти-il-1-бета антитела и способы их применения | |
| JP2017534646A5 (cg-RX-API-DMAC7.html) | ||
| RU2020124153A (ru) | Гуманизированные антитела к cd19 человека и способы их применения | |
| RU2017120361A (ru) | Антитела к pdgf-b и способы их применения | |
| RU2017119543A (ru) | Анти-tim3 антитела и способы их применения | |
| HRP20211641T1 (hr) | Bispecifična protutijela anti-vegf/anti-ang-2 i njihova primjena u liječenju vaskularnih očnih bolesti | |
| RU2015102069A (ru) | Антитела к биотину и способы их применения | |
| RU2017111228A (ru) | Композиции антитела против IL-7R | |
| RU2016137110A (ru) | Антитела к компоненту комплемента с5 | |
| HRP20240719T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba | |
| RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
| JP2015523380A5 (cg-RX-API-DMAC7.html) | ||
| JP2014511179A5 (cg-RX-API-DMAC7.html) | ||
| JP2016508496A5 (cg-RX-API-DMAC7.html) | ||
| RU2013143358A (ru) | Анти-fgfr4 антитела и способы их применения | |
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| RU2017102514A (ru) | Гуманизированные анти-тау-антитела | |
| JP2018505177A5 (cg-RX-API-DMAC7.html) | ||
| JP2017534645A5 (cg-RX-API-DMAC7.html) | ||
| JP2020511947A5 (cg-RX-API-DMAC7.html) | ||
| RU2017120360A (ru) | Биспецифические антитела и способы их применения в офтальмологии | |
| HRP20201493T1 (hr) | Anti-alfa-sinukleinska protutijela i postupci uporabe | |
| HRP20201399T1 (hr) | Novi modulatori i postupci njihove uporabe | |
| JP2011506483A5 (cg-RX-API-DMAC7.html) | ||
| RU2018123717A (ru) | Комбинированные лечения, их применения и способы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20200325 |